In 2023, the top 10 drugs purchased under the 340B Drug Pricing Program accounted for roughly one-third of the program's total spending, according to a Health Resources and Services Administration news release.
Here is a breakdown of the 10 priciest 340B medications:
- Keytruda (oncology): $6.91 billion in sales
- Biktarvy (HIV): $3.58 billion
- Opdivo (oncology): $1.95 billion
- Darzalex Faspro (oncology): $1.89 billion
- Ocrevus (oncology): $1.85 billion
- Trikafta (cystic fibrosis): $1.82 billion
- Humira (CF) Pen (immunology): $998.8 million
- Descovy (HIV): $969.5 million
- Entyvio (immunology): $949.7 million
- Durvalumab (oncology): $889.6 million